KidneyMAP®

Myriad RBM HumanMAPs

Rules-Based Medicine’s KidneyMAP panels detect early signs of renal damage which is a common problem in drug development programs. Developed in conjunction with the Predictive Safety Testing Consortium, it provides a sensitive and quantitative method to detect the earliest stages of drug-induced kidney injury. This will allow researchers to efficiently prioritize drug compounds and to accelerate decisions on exploratory and clinical testing protocols.

Serum/Plasma Biomarkers v. 1.0

1 This assay did not meet performance specifications in EDTA-Plasma and results should be used for information purposes only.

2 This assay did not meet performance specifications in Serum and results should be used for information purposes only.

Intended for Research Use Only.

Serum or plasma Other fluids*
110 µL 350 µL
*Cerebrospinal fluid, tissue culture supernatants,  bronchoalveolar lavage, synovial fluid, tissue extracts, tears, skin washings, etc.

Bibliography

Kidney Function and Toxicity

2023

Urinary markers differentially associate with kidney inflammatory activity and chronicity measures in patients with lupus nephritis (2023) Ahmad Akhgar, Dominic Sinibaldi, Lingmin Zeng, Alton B Farris III, Jason Cobb, Monica Battle, David Chain, Jennifer A Cann, Gabor G Illei, S Sam Lim , Wendy I White Lupis Science and Medicine

Back To Top

2020

Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-?RI inhibitor galunisertib. (2020) Giannelli G, Santoro A, Kelley RK, Gane E, Paradis V, Cleverly A, Smith C, Estrem ST, Man M, Wang S, Lahn MM, Raymond E, Benhadji KA, Faivre S PLoS One
 
 

The utility of novel urinary biomarkers in mice for drug development studies (2020) Adedeji AO, Gu YZ, Pourmohamad T, Kanerva J, Chen Y, Atabakhsh E, Tackett MR, Chen F, Bhatt B, Gury T, Dorchies O, Sonee M, Morgan M, Burkey J, Gautier JC, McDuffie JE International Journal of Toxicology
 
Therapy Indications
 

Back To Top

2019

Metabolomic analyses reveal lipid abnormalities and hepatic dysfunction in non-human primate model for Yersinia pestis (2019) Gautam A, Muhie S, Cakraborty N, Hoke A, Donohue D, Miller SA, Hammamieh R, Jett M Metabolomics
 
 

External Validation of a Pre-Transplant Biomarker Model (REVERSE) Predictive of Renal Recovery after Liver Transplantation (2019) Levitsky J, Asrani SK, Abecassis M, Ruiz R, Jennings LW, Klintmalm G Hepatology

Biomarker panels associated with progression of renal disease in type 1 diabetes. (2019) Colombo M, Valo E, McGurnaghan SJ, Sandholm N, Blackbourn LAK, Dalton RN, Dunger D, Groop PH, McKeigue PM, Forsblom C, Colhoun HM Diabetologia

Impaired kidney structure and function in spinal muscular atrophy (2019) Nery FC, Siranosian JJ, Rosales I, Deguise MO, Sharma A, Muhtaseb AW, Nwe P, Johnstone AJ, Zhang R, Fatouraei M, Huemer N, Alves CRR, Kothary R, Swoboda KJ Neurology Genetics
 
Therapy Indications
 

Therapy with 2'O methly phosphorothioate antisense oligonucleotides causes reversible proteinuria by inhibiting renal protien reabsorption (2019) Janssen MJ, Nieskens TTG, Steevels TAM, Caetano-Pinto P, den Braanker D, Mulder M, Ponstein Y, Jones S, Masereeuw R, den Besten C, Wilmber MJ Molecular Therapy Nucleic Acids
 
Therapy Indications
 

Discovery and validation of a biomarker model (preserve) predictive of renal outcomes after liver transplantation (2019) Levitsky J, Asrani SK, Klintmalm G, Schiano T, Moss A, Chavin K, Miller C, Guo K, Zhao L, Jennings LW, Brown M, Armstrong B, Abecassis M Hepatology
 
Therapy Indications
 

Methionine restriction delays aging-related urogenital diseases in male Fischer 344 rats. (2019) Komninou D, Malloy VL, Zimmerman JA, Sinha R, Richie JP Jr GeroScience
 
Therapy Indications
 

Novel Biomarkers for Change in Renal Function in People With Dysglycemia. (2019) Gerstein HC, Pare G, McQueen MJ, Lee SF, Bangdiwala SI, Kannt A, Hess A, ORIGIN Trial Investigators Diabetes Care

Development of a prognostic composite cytokine signature based on the correlation with nivolumab clearance: translational PK/PD analysis in patients with renal cell carcinoma. (2019) Wang R, Zheng J, Shao X, Ishii Y, Roy A, Bello A, Lee R, Zhang J, Wind-Rotolo M, Feny Y Journal for ImmunoTherapy of Cancer

Back To Top

2018

Biomarkers of diabetic kidney disease (2018) Colhoun HM, Marcovecchio ML Diabetologia
 
Therapy Indications
 

Serum kidney injury molecule 1 and B2-microglobulin perform as well as larger biomarker panels for prediction of rapid decline in renal function in type 2 diabetes (2018) Colombo M, Looker HC, Farran B, Hess S, Groop L, Palmer CNA, Brosnan MJ, Dalton RN, Wong M, Turner C, Ahlqvist E, Dunger D, Agakov F, Durrington P, Livingstone S, Betteridge J, McKeigue PM, Colhoun HM Diabetologia

Drug-induced Obstructive and Retrograde Nephropathy Associated with a2u-globulin in Male Rats (2018) Jacobsen B, Freichel C, Eichinger-Chapelon A, Brink A, Hoflack JC, Albassam M, Lenz B Toxocologic Pathology
 
Therapy Indications
 

Back To Top

2017

Perspectives on using a multiplex human kidney safety biomarker panel to detect cisplatin-induced tubular toxicity in male and female Cynomolgus monkeys. (2017) Chen Y, Dale Thurman J, Kinter LB, Bialecki R, Eric McDuffie J Toxicol Appl Pharmacol.
 
Therapy Indications
 

Back To Top

2016

The dipeptidyl peptidase inhibitor linagliptin and the angiotensin II receptor blocker telmisartan show renal benefit by different pathways in rats with 5/6 nephrectomy (2016) Tsuprykov O, Ando R, Reichetzeder C, von Websky K, Antonenko V, Sharkovska Y, Chaykovska L, Rahnenf?hrer J, Hasan AA, Tammen H, Alter M, Klein T, Ueda S, Yamagishi S, Okuda S, Hocher B Kidney International
 
Therapy Indications
 

Evaluation of Novel Biomarkers of Nephrotoxicity in Cynomolgus Monkeys Treated with Gentamicin (2016) Gautier J-C, Zhou X, Yang Y, Gury T, Qu Z, Palazzi X, L?onard J-F, Slaoui M, Veeranagouda Y, Guizon I, Boitier E, Filali-Ansary A, van den Berg BHJ, Poetz O, Joos T, Zhang T, Wang J, Detilleux P, Li B Toxicology and Applied Pharmacology
 
Therapy Indications
 

A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of treatment with sirukumab (CNTO 136) in patients with active lupus nephritis (2016) Rovin B, van Vollenhoven R, Aranow C, Wagner C, Gordon R, Zhuang Y, Belkowski S, Hsu B Arthritis & Rheumatology

Assessment of Urine Proteomics in Type 1 Primary Hyperoxaluria*American Journal of Nephrology (2016) Brooks ER, Hoppe B, Milliner DS, Salido E, Rim J, Krevitt LM, Olson JB, Price HE, Vural G, Langman CB American Journal of Nephrology
 
Therapy Indications
 

Circulating Biomarkers and Outcome from a Randomised Phase Ii Trial of Sunitinib Vs Everolimus for Patients with Metastatic Renal Cell Carcinoma (2016) Voss MH, Chen D, Marker M, Hakimi AA, Lee C-H, Hsieh JJ, Knox JJ, Voi M, Motzer RJ British Journal of Cancer
 
 

Plasma cystatin C and neutrophil gelatinase-associated lipocalin in relation to coronary atherosclerosis on intravascular ultrasound and cardiovascular outcome: Impact of kidney function (ATHEROREMO-IVUS study). (2016) Brankovic M, Akkerhuis KM, Buljubasic N, Cheng JM, Oemrawsingh RM, Garcia-Garcia HM, Regar E, Serruys PW, van Geuns RJ, Boersma E, Kardys I. Atherosclerosis

Investigative Nonclinical Cardiovascular Safety and Toxicology Studies with BMS-986094, an NS5b RNA-Dependent RNA Polymerase Inhibitor (2016) Gill M, Horn K, Hennan J, White R, Bounous D, Clark S, Megill JR, Janovitz E, Davies M, Sanderson T, Graziano M. Toxicol Sci
 
Therapy Indications
 

Pentraxin-2 suppresses c-Jun/AP-1 signaling to inhibit progressive fibrotic disease (2016) Nakagawa N, Barron L, Gomez IG, Johnson BG, Roach AM, Kameoka S, Jack RM, Lupher ML, Gharib SA, Duffield JS JCI Insight
 
Therapy Indications
 

Back To Top

2015

Biomarkers of rapid chronic kidney disease progression in type 2 diabetes (2015) Looker HC, Colombo M, Hess S, Brosnan MJ, Farran B, Dalton RN, Wong MC, Turner C, Palmer CNA, Nogceke E, Groop L, Salomaa V, Dunger DB, Agakov F, McKeigue PM, Colhoun HM Kidney International

Toxicity of aerosols of nicotine and pyruvic acid (separate and combined) in Sprague?Dawley rats in a 28-day OECD 412 inhalation study and assessment of systems toxicology (2015) Phillips B, Esposito M, Verbeeck J, Bou? S, Iskandar A, Vuillaume G, Leroy P, Krishnan S, Kogel U, Utan A, Schlage WK, Bera M, Veljkovic E, Hoeng J, Peitsch MC, Vanscheeuwijck P Inhal Toxicol.
 
Therapy Indications
 

Cerium oxide nanoparticles attenuate acute kidney injury induced by intra-abdominal infection in Sprague?Dawley rats (2015) Manne ND, Arvapalli R, Nepal N, Shokuhfar T, Rice KM, Asano S, Blough ER J Nanobiotechnology
 
Therapy Indications
 

Systems Biology Reveals Cigarette Smoke-Induced Concentration-Dependent Direct and Indirect Mechanisms That Promote Monocyte-Endothelial Cell Adhesion. (2015) Poussin C, Laurent A, Peitsch MC, Hoeng J, De Leon H Toxicol Sci.

Characterization of Renal Biomarkers for Use in Clinical Trials: Effect of Preanalytical Processing and Qualification Using Samples from Subjects with Diabetes (2015) Brott DA, Furlong ST, Adler SH, Hainer JW, Arani RB, Pinches M, Rossing P, Chaturvedi N Drug Design, Development and Therapy
 
Therapy Indications
 

Comparison of Plasma and Urine Biomarker Performance in Acute Kidney Injury (2015) Schley G, K?berle C, Manuilova E, Rutz S, Forster C, Weyand M, Formentini I, Kientsch-Engel R, Eckardt K-U, Willam C PLoS ONE
 
Therapy Indications
 

Back To Top

2014

Normal Ranges and Variability of Novel Urinary Renal Biomarkers in Sprague-Dawley Rats (2014) Gautier JC, Gury T, Guffroy M, Khan-Malek R, Hoffman D, Pettit S, Harpur E Toxicol Pathol. 2014 Apr 7. [Epub ahead of print]
 
Therapy Indications
 

Comparison between Male and Female Sprague-Dawley Rats in the Response of Urinary Biomarkers to Injury Induced by Gentamicin (2014) Gautier JC, Gury T, Guffroy M, Masson R, Khan-Malek R, Hoffman D, Pettit S, Harpur E Toxicol Pathol. 2014 Apr 9. [Epub ahead of print]
 
Therapy Indications
 

CD47 Blockade Reduces Ischemia-Reperfusion Injury and Improves Outcomes in a Rat Kidney Transplant Model (2014) Lin Y, Manning PT, Jia J, Gaut JP, Xiao Z, Capoccia BJ, Chen CC, Hiebsch RR, Upadhya G, Mohanakumar T, Frazier WA, Chapman WC Transplantation. 2014 Jun 30. [Epub ahead of print]
 
Therapy Indications
 

Plasma protein biomarkers enhance the clinical prediction of kidney injury recovery in patients undergoing liver transplantation. (2014) Levitsky J, Baker TB, Jie C, Ahya S, Levin M, Friedewald J, Al-Saden P, Salomon DR, Abecassis MM. Hepatology 2014 Jul 31. doi: 10.1002/hep.27346. [Epub ahead of print]
 
Therapy Indications
 

Deferasirox effect on renal haemodynamic parameters in patients with transfusion-dependent ? thalassaemia. (2014) Piga A, Fracchia S, Lai ME, Cappellini MD, Hirschberg R, Habr D, Wegener A, Bouillaud E, Forni GL. Br J Haematol. 2014 Nov 17. doi: 10.1111/bjh.13217. [Epub ahead of print]
 
Therapy Indications
 

CXCR4 promotes renal tubular cell survival in male diabetic rats: implications for ligand inactivation in the human kidney. (2014) Siddiqi FS, Chen L, Advani SL, Thai K, Batchu SN, Alghamdi TA, White KE, Sood MM, Gibson IW, Connelly KA, Marsden PA, Advani A. Endocrinology. 2014 Dec 30:en20141650. [Epub ahead of print]

Dipeptidyl Peptidase-4 Inhibition Improves Left Ventricular Function in Chronic Kidney Disease (2014) Connelly KA, Bowskill BB, Advani SL, Thai K, Chen L-H, Kabir MG, Gilbert RE, Advani A Clinical & Investigative Medicine
 
Therapy Indications
 

Back To Top

2013

EFFECTS OF CONTRAST MEDIA ON DIFFERENT URINARY BIOMARKERS OF KIDNEY INJURY (2013) Steffgen J, Blaschke S, Brun-Schulte-Wissing N, Pagel P, Huber F, Mapes J, Jaehnige A, Pestel S Nephrol. Dial. Transplant. (2013) 28 (suppl 1): i331-i351.
 
Therapy Indications
 

Urinary cystatin C as a renal biomarker and its immunohistochemical localization in anti-GBM glomerulonephritis rats (2013) Togashi Y, Imura N, Miyamoto Y Exp Toxicol Pathol. 2013 Jun 20. pii: S0940-2993(13)00076-6
 
Therapy Indications
 

Allogeneic mesenchymal stem cell infusion for the stabilization of focal segmental glomerulosclerosis (2013) Belingheri M, Lazzari L, Parazzi V, Groppali E, Biagi E, Gaipa G, Giordano R, Rastaldi MP, Croci D, Biondi A, Rebulla P, Edefonti A, Ghio L Biologicals. 2013 Oct 14. pii: S1045-1056(13)00111-5. doi: 10.1016/j.biologicals.2013.09.004
 
Therapy Indications
 

Leucine-Rich Repeat Kinase 2 (Lrrk2)-Deficient Rats Exhibit Renal Tubule Injury and Perturbations in Metabolic and Immunological Homeostasis (2013) Ness D, Ren Z, Gardai S, Sharpnack D, Johnson VJ, Brennan RJ, Brigham EF, Olaharski AJ PLoS ONE

Back To Top

2012

Association of Estimated Glomerular Filtration Rate and Urinary Uromodulin Concentrations with Rare Variants Identified by UMOD Gene Region Sequencing (2012) K?ttgen A, Yang Q, Shimmin LC, Tin A, Schaeffer C, Coresh J, Liu X, Rampoldi L, Hwang S, Boerwinkle E, Hixson JE, Linda Kao WH, Fox CS PLoS ONE 7(5): e38311
 
Therapy Indications
 

Urinary cystatin C as a biomarker for diabetic nephropathy and its immunohistochemical localization in kidney in Zucker diabetic fatty (ZDF) rats (2012) Togashi Y, Miyamoto Y Exp Toxicol Pathol. 2012 Jul 11
 
Therapy Indications
 

Effects of Stimulation of Soluble Guanylate Cyclase on Diabetic Nephropathy in Diabetic eNOS Knockout Mice on Top of Angiotensin II Receptor Blockade (2012) Ott IM, Alter ML, von Websky K, Kretschmer A, Tsuprykov O, Sharkovska Y, Krause-Relle K, Raila J, Henze A, Stasch JP, Hocher B PLoS One. 2012;7(8):e42623. Epub 2012 Aug 10

Early Urinary and Plasma Biomarkers for Experimental Diabetic Nephropathy (2012) Alter ML, Kretschmer A, Von Websky K, Tsuprykov O, Reichetzeder C, Simon A, JP Stasch, Hoche B Clin. Lab. 2012;58:659-671
 
Therapy Indications
 

Toxicity Profile of Small-Molecule IAP Antagonist GDC-0152 is Linked to TNF-Alpha Pharmacology (2012) Erickson RI, Tarrant J, Cain G, Lewin-Koh SC, Dybdal N, Wong H, Blackwood E, West K, Steigerwalt R, Mamounas M, Flygare JA, Amemiya K, Dambach D, Fairbrother WJ, Diaz D Toxicol Sci. 2012 Sep 5. [Epub ahead of print]
 
Therapy Indications
 

DPP-4 Inhibition on Top of Angiotensin Receptor Blockade Offers a New Therapeutic Approach for Diabetic Nephropathy (2012) Altera ML, Ottb IM, von Webskyb K, Tsuprykovb O, Sharkovska Y, Krause-Relle K, Raila, J, Henze A, Klein T, Hocher B Kidney Blood Press Res 2012;36:119-130
 
Therapy Indications
 

Mapping creatinine- and cystatin C-related white matter brain deficits in the elderly (2012) Rajagopalan P, Refsum H, Hua X, Toga AW, Jack CR Jr, Weiner MW, Thompson PM; Alzheimer's Disease Neuroimaging Initiative Neurobiol Aging. 2012 Nov 19. pii: S0197-4580(12)00533-7

Back To Top

2011

The Role of Residual Gadolinium in the Induction of Nephrogenic Systemic Fibrosis-Like Skin Lesions in Rats (2011) Pietsch H, Raschke M, Ellinger-Ziegelbauer H, Jost G, Walter J, Frenzel T, Lenhard D, H?tter J, Sieber MA Invest Radiol. 46: 48-56.
 
Therapy Indications
 

Assessment of Biomarkers of Drug-induced Kidney Injury in Cynomolgus Monkeys Treated with a Triple Re-uptake Inhibitor (2011) Guha M, Heier A, Price S, Bielenstein M, Caccese RG, Heathcote DI, Simpson TR, Stong DB, Bodes E Toxicol Sci. 2011 Jan 22. [Epub ahead of print]
 
Therapy Indications
 

Urinary biomarkers in hexachloro-1:3-butadiene-induced acute kidney injury in the female Hanover Wistar rat; correlation of a-glutathione S-transferase, albumin and kidney injury molecule-1 with histopathology and gene expression (2011) Swain A, Turton J, Scudamore CL, Pereira I, Viswanathan N, Smyth R, Munday M, McClure F, Gandhi M, Sondh S, York M J Appl Toxicol. [Epub ahead of print]
 
Therapy Indications
 

Clinical and Plasma Proteomic Markers Correlating With Chronic Kidney Disease After Liver Transplantation (2011) Levitsky J, Salomon DR, Abecassis M, Langfelder P, Horvath S, Friedewald J, Wang E, Kurian SM, Mondala T, Gil S, McDade R, Ballard K, Gallon L Am J Transplant. 2011 Jul 27.
 
Therapy Indications
 

Trefoil Factor 3 Predicts Incident Chronic Kidney Disease: A Case-Control Study Nested within the Atherosclerosis Risk in Communities (ARIC) Study (2011) Astor BC, K?ttgen A, Hwang SJ, Bhavsar N, Fox CS, Coresh J Am J Nephrol. 2011 Aug 9;34(4):291-297.
 
Therapy Indications
 

Pharmacological inhibition of myostatin suppresses systemic inflammation and muscle atrophy in mice with chronic kidney disease (2011) Zhang L, Rajan V, Lin E, Hu Z, Han HQ, Zhou X, Song Y, Min H, Wang X, Du J, Mitch WE FASEB J. 2011 May;25(5):1653-63

Lower urinary connective tissue growth factor levels and incident CKD stage 3 in the general population (2011) O'Seaghdha CM, Hwang SJ, Bhavsar NA, K?ttgen A, Coresh J, Astor BC, Fox CS Am J Kidney Dis. 2011 Jun;57(6):841-9
 
Therapy Indications
 

Urinary cystatin C as a biomarker for acute kidney injury and its immunohistochemical localization in kidney in the CDDP-treated rats (2011) Togashi Y, Sakaguchi Y, Miyamoto M, Miyamoto Y Exp Toxicol Pathol. 2011 Mar 4. [Epub ahead of print]
 
Therapy Indications
 

Comparison of the course of biomarker changes and kidney injury in a rat model of drug-induced acute kidney injury (2011) Sasaki D, Yamada A, Umeno H, Kurihara H, Nakatsuji S, Fujihira S, Tsubota K, Ono M, Moriguchi A, Watanabe K, Seki J Biomarkers. 2011 Sep 28. [Epub ahead of print]
 
Therapy Indications
 

Intratracheal instillation of cerium oxide nanoparticles induces hepatic toxicity in male Sprague-Dawley rats (2011) Nalabotu SK, Kolli MB, Triest WE, Ma JY, Manne NDPK, Katta A, Addagarla HS, Rice KM, Blough ER International Journal of Nanomedicine Volume 2011:6 Pages 2327 - 2335
 
Therapy Indications
 

Biomarkers for drug-induced renal damage and nephrotoxicity-an overview for applied toxicology (2011) Fuchs TC, Hewitt P AAPS J. 2011 Dec;13(4):615-31
 
Therapy Indications
 

Back To Top

2010

Plasma epidermal growth factor levels predict cognitive decline in Parkinson disease (2010) Chen-Plotkin AS, Hu WT, Siderowf A, Weintraub D, Goldmann Gross R, Hurtig HI, Xie SX, Arnold SE, Grossman M, Clark CM, Shaw LM, McCluskey L, Elman L, Van Deerlin VM, Lee VM, Soares H, Trojanowski JQ Ann Neurol. Nov 29. [Epub ahead of print]

Recommendations to qualify biomarker candidates of drug-induced liver injury (2010) Ozer JS, Chetty R, Kenna G, Koppiker N, Karamjeet P, Li D, Palandra J, Lanevschi A, Souberbielle BE, Ramaiah S Biomark Med 4: 475-483.
 
Therapy Indications
 

Urinary clusterin, cystatin C, ?2-microglobulin and total protein as markers to detect drug-induced kidney injury (2010) Dieterle F, Perentes E, Cordier A, Roth DR, Verdes P, Grenet O, Pantano S, Moulin P, Wahl D, Mahl A, End P, Staedtler F, Legay F, Carl K, Laurie D, Chibout SD, Vonderscher J, Maurer G Nat Biotechnol 28: 463-469.
 
Therapy Indications
 

Kidney injury molecule-1 outperforms traditional biomarkers of kidney injury in preclinical biomarker qualification studies (2010) Vaidya VS, Ozer JS, Dieterle F, Collings FB, Ramirez V, Troth S, Muniappa N, Thudium D, Gerhold D, Holder DJ, Bobadilla NA, Marrer E, Perentes E, Cordier A, Vonderscher J, Maurer G, Goering PL, Sistare FD, Bonventre JV Nat Biotechnol. 28: 478-85.
 
Therapy Indications
 

A panel of urinary biomarkers to monitor reversibility of renal injury and a serum marker with improved potential to assess renal function (2010) Ozer JS, Dieterle F, Troth S, Perentes E, Cordier A, Verdes P, Staedtler F, Mahl A, Grenet O, Roth DR, Wahl D, Legay F, Holder D, Erdos Z, Vlasakova K, Jin H, Yu Y, Muniappa N, Forest T, Clouse HK, Reynolds S, Bailey WJ, Thudium DT, Topper MJ, Skopek TR, Sina JF, Glaab WE, Vonderscher J, Maurer G, Chibout SD, Sistare FD, Gerhold DL Nat Biotechnol.28: 444-5.
 
Therapy Indications
 

A guidance for renal biomarker lead optimization and use in translational pharmacodynamics (2010) Ozer JS Drug Discov Today15: 142-7.
 
Therapy Indications
 

Uromodulin levels associate with a common UMOD variant and risk for incident CKD (2010) K?ttgen A, Hwang SJ, Larson MG, Van Eyk JE, Fu Q, Benjamin EJ, Dehghan A, Glazer NL, Kao WH, Harris TB, Gudnason V, Shlipak MG, Yang Q, Coresh J, Levy D, Fox CS J Am Soc Nephrol 21: 337-344.
 
Therapy Indications
 

Back To Top

2009

Distinct functions of activated protein C differentially attenuate acute kidney injury (2009) Gupta A, Gerlitz B, Richardson MA, Bull C, Berg DT, Syed S, Galbreath EJ, Swanson BA, Jones BE, Grinnell BW J Am Soc Nephrol. 20: 267-77.
 
Therapy Indications
 

Analysis of Renal Biomarkers in Samples of Rat Urine Samples Frozen for 44 months From a Study on Puromycin Amino Nucleoside (PAN) (2009) Perron MF, Burnett R, Reiniche A, Briffaux JP, Eisinger D, K?sters S and Mapes J Toxicology LettersVolume 189, Supplement 1, S159
 
Therapy Indications
 

The involvement of pro-inflammatory cytokines in nephrogenic systemic fibrosis - a mechanistic hypothesis based on preclinical results from a rat model treated with gadodiamide. (2009) Steger-Hartmann T, Raschke M, Riefke B, Pietsch H, Sieber MA, Walter J Exp Toxicol Pathol 61: 537-552.

The Liver Toxicity Biomarker Study: Phase I Design and Preliminary Results. (2009) McBurney RN, Hines WM, Von Tungeln LS, Schnackenberg LK, Beger RD, Moland CL, Han T, Fuscoe JC, Chang CW, Chen JJ, Su Z, Fan XH, Tong W, Booth SA, Balasubramanian R, Courchesne PL, Campbell JM, Graber A, Guo Y, Juhasz PJ, Li TY, Lynch MD, Morel NM, Plasterer TN, Takach EJ, Zeng C, Beland FA Toxicol Pathol 37: 52-64.
 
Therapy Indications
 

Back To Top

2008

Tissue distribution and toxicity of intravenously administered titanium dioxide nanoparticles in rats. (2008) Fabian E, Landsiedel R, Ma-Hock L, Wiench K, Wohlleben W, van Ravenzwaay B Arch Toxicol 82: 151-157.

Endothelial activation markers in anemic non-dialysis chronic kidney disease patients. (2008) Patel TV, Mittal BV, Keithi-Reddy SR, Duffield JS, Singh AK Nephron Clin Pract 110: c244-250.

Back To Top

2007

Activated protein C ameliorates LPS-induced acute kidney injury and downregulates renal INOS and angiotensin 2. (2007) Gupta A, Rhodes GJ, Berg DT, Gerlitz B, Molitoris BA, Grinnell BW Am J Physiol Renal Physiol 293: F245-F254.
 
Therapy Indications
 

Role of protein C in renal dysfunction after polymicrobial sepsis (2007) Gupta A, Berg DT, Gerlitz B, Sharma GR, Syed S, Richardson MA, Sandusky G, Heuer JG, Galbreath EJ, Grinnell BW J Am Soc Nephrol. 2007 Mar;18(3):860-7
 
Therapy Indications
 

Every Order Starts With a Quote

Thank you for your interest in RBM's innovative biomarker solutions. Please tell us more about what you would like to order and provide us with your details, so we can get back to you with a quote.